Clinically Relevant Immune Responses against Cytomegalovirus : Implications for Precision Medicine
Immune responses to human cytomegalovirus (CMV) can be used to assess immune fitness in an individual. Further to its clinical significance in posttransplantation settings, emerging clinical and translational studies provide examples of immune correlates of protection pertaining to anti-CMV immune responses in the context of cancer or infectious diseases, e.g., tuberculosis. In this viewpoint, we provide a brief overview about CMV-directed immune reactivity and immune fitness in a clinical context and incorporate some of our own findings obtained from peripheral blood or tumour-infiltrating lymphocytes (TIL) from patients with advanced cancer. Observations in patients with solid cancers whose lesions contain both CMV and tumour antigen-specific T-cell subsets are highlighted, due to a possible CMV-associated "bystander" effect in amplifying local inflammation and subsequent tumour rejection. The role of tumour-associated antibodies recognising diverse CMV-derived epitopes is also discussed in light of anti-cancer immune responses. We discuss here the use of anti-CMV immune responses as a theranostic tool-combining immunodiagnostics with a personalised therapeutic potential-to improve treatment outcomes in oncological indications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 20(2019), 8 vom: 23. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lérias, Joana R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 19.08.2019 Date Revised 25.02.2020 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms20081986 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM29638691X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM29638691X | ||
| 003 | DE-627 | ||
| 005 | 20231225085727.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms20081986 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0987.xml |
| 035 | |a (DE-627)NLM29638691X | ||
| 035 | |a (NLM)31018546 | ||
| 035 | |a (PII)E1986 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lérias, Joana R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinically Relevant Immune Responses against Cytomegalovirus |b Implications for Precision Medicine |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.08.2019 | ||
| 500 | |a Date Revised 25.02.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Immune responses to human cytomegalovirus (CMV) can be used to assess immune fitness in an individual. Further to its clinical significance in posttransplantation settings, emerging clinical and translational studies provide examples of immune correlates of protection pertaining to anti-CMV immune responses in the context of cancer or infectious diseases, e.g., tuberculosis. In this viewpoint, we provide a brief overview about CMV-directed immune reactivity and immune fitness in a clinical context and incorporate some of our own findings obtained from peripheral blood or tumour-infiltrating lymphocytes (TIL) from patients with advanced cancer. Observations in patients with solid cancers whose lesions contain both CMV and tumour antigen-specific T-cell subsets are highlighted, due to a possible CMV-associated "bystander" effect in amplifying local inflammation and subsequent tumour rejection. The role of tumour-associated antibodies recognising diverse CMV-derived epitopes is also discussed in light of anti-cancer immune responses. We discuss here the use of anti-CMV immune responses as a theranostic tool-combining immunodiagnostics with a personalised therapeutic potential-to improve treatment outcomes in oncological indications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a T cells | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a cytomegalovirus | |
| 650 | 4 | |a immune responses | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a interferon gamma | |
| 700 | 1 | |a Paraschoudi, Georgia |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Inês |e verfasserin |4 aut | |
| 700 | 1 | |a Martins, João |e verfasserin |4 aut | |
| 700 | 1 | |a de Sousa, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Condeço, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Figueiredo, Nuno |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalho, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Dodoo, Ernest |e verfasserin |4 aut | |
| 700 | 1 | |a Jäger, Elke |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Maeurer, Markus |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 20(2019), 8 vom: 23. Apr. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2019 |g number:8 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms20081986 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2019 |e 8 |b 23 |c 04 | ||